NovoCure Reports Q3 2026 Financial Results
NovoCure Limited reported third-quarter 2026 financial results, showing a net loss of $0.09 per share and revenue of $193.4 million, both exceeding analyst expectations.
Stocks · News reference
NovoCure Q3 2026 Earnings Call Transcript
NovoCure (NASDAQ:NVCR) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — NovoCure Ltd (NVCR)
Filed: 2026-10-29 AccNo: 0001645113-26-000081 Size: 366 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Analyst Jason Bednar Maintains Buy Rating for Novocure
Piper Sandler analyst Jason Bednar has reaffirmed a 'Buy' rating and a $29 price target for Novocure (NVCR).